The FDA's campaign against substandard pharmaceutical products manufactured in India is continuing with a new import ban, this time imposed on drugs produced at a Bangalore facility owned and operated by Canadian company Apotex Inc.

Mumbai-based pharmaceutical firm Wockhardt Ltd has announced that it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding the import alert on production originating from the company's Waluj facility in India.